Erin E. Congdon

Tau-targeting therapies for Alzheimer disease: current status and future directions

Single-domain antibody–based noninvasive in vivo imaging of α-synuclein or tau pathology

Single domain antibodies targeting pathological tau protein: Influence of four IgG subclasses on efficacy and toxicity

Targeting tau only extracellularly is likely to be less efficacious than targeting it both intra- and extracellularly

Dynamics of Internalization and Intracellular Interaction of Tau Antibodies and Human Pathological Tau Protein in a Human Neuron-Like Model

Increased neuronal activity in motor cortex reveals prominent calcium dyshomeostasis in tauopathy mice

Tau antibody chimerization alters its charge and binding, thereby reducing its cellular uptake and efficacy

Tau-targeting therapies for Alzheimer disease

Sex Differences in Autophagy Contribute to Female Vulnerability in Alzheimer's Disease

Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy

Harnessing the Immune System for Treatment and Detection of Tau Pathology

Antibody Uptake into Neurons Occurs Primarily via Clathrin-dependent Fcγ Receptor Endocytosis and Is a Prerequisite for Acute Tau Protein Clearance

Two Novel Tau Antibodies Targeting the 396/404 Region Are Primarily Taken Up by Neurons and Reduce Tau Protein Pathology